

Digoxin Does Not Accelerate Progression of Diabetic Retinopathy

THOMAS W. GARDNER, MD
RONALD KLEIN, MD, MPH
SCOT E. MOSS, MA

FREDERICK L. FERRIS III, MD
NANCY A. REMALEY, MS

OBJECTIVE — To test the hypothesis that digoxin, an inhibitor of $\text{Na}^+ - \text{K}^+ - \text{ATPase}$ activity, accelerates the progression of diabetic retinopathy.

RESEARCH DESIGN AND METHODS — We compared the incidence and risk of retinopathy in 120 digoxin-taking vs. 867 non-digoxin-taking diabetic participants in the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) and in 117 digoxin-taking vs. 1,883 non-digoxin-taking diabetic subjects in the Early Treatment Diabetic Retinopathy Study (ETDRS). In both studies, retinopathy was detected by grading stereoscopic color photographs using the modified Airlie House classification scheme, and a two-step difference in baseline retinopathy grade was considered significant.

RESULTS — After controlling for other risk factors, we found no statistically significant association with either 4-year incidence of retinopathy (WESDR) or progression of retinopathy (WESDR and ETDRS) in patients taking digoxin at baseline compared with those not taking digoxin.

CONCLUSIONS — These data suggest that digoxin therapy does not adversely affect the course of diabetic retinopathy.

Patients and animals with diabetes have reduced vascular and neural $\text{Na}^+ - \text{K}^+ - \text{ATPase}$ activity (1,2), which may be related to the pathogenesis of vascular complications, including retinopathy (3,4). Patients with diabetic retinopathy may have concurrent congestive heart failure or cardiac arrhythmias that

From the Department of Ophthalmology (T.W.G.), Pennsylvania State University College of Medicine, Hershey, Pennsylvania; the Department of Ophthalmology (R.K., S.E.M.), University of Wisconsin School of Medicine, Madison, Wisconsin; and the National Eye Institute (F.L.F., N.A.R.), National Institutes of Health, Bethesda, Maryland.

Address correspondence and reprint requests to Thomas W. Gardner, MD, Department of Ophthalmology, Pennsylvania State University School of Medicine, 500 University Dr., Hershey, PA 17033.

Received for publication 4 May 1994 and accepted in revised form 22 September 1994.

WESDR, Wisconsin Epidemiologic Study of Diabetic Retinopathy; ETDRS, Early Treatment Diabetic Retinopathy Study; PDR, proliferative diabetic retinopathy; CI, confidence interval; OR, odds ratio.

require treatment with digoxin. Digoxin improves myocardial contractility and slows cardiac electrical conduction by binding to and inhibiting the catalytic site of $\text{Na}^+ - \text{K}^+ - \text{ATPase}$. It is thus possible that digoxin treatment might further reduce already depressed $\text{Na}^+ - \text{K}^+ - \text{ATPase}$ activity in patients with diabetes. We hypothesized, therefore, that reduction of $\text{Na}^+ - \text{K}^+ - \text{ATPase}$ activity by both diabetes and digoxin might accelerate progression of diabetic retinopathy. Therefore, we used data from the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) and the Early Treatment Diabetic Retinopathy Study (ETDRS) to determine if digoxin had an adverse effect on the course of diabetic retinopathy in digoxin-treated subjects versus non-treated subjects.

RESEARCH DESIGN AND METHODS

Both the WESDR and the ETDRS are longitudinal cohort studies of people with diabetes that can provide progression rates of diabetic retinopathy in those taking or not taking digoxin. The details of their study designs have been previously published (5–7). The WESDR is a long-term natural history study of 2,990 diabetic people in an 11-county area in southern Wisconsin, in whom diabetes was diagnosed in 1,210 at <30 years of age and in 1,780 at ≥ 30 years of age. The ETDRS is a clinical trial of aspirin use and photocoagulation in 3,711 patients with mild nonproliferative to early proliferative diabetic retinopathy (PDR), of whom 1,444 were classified as having type I diabetes and 2,267 were classified as having type II diabetes (2,000 without proliferative retinopathy at baseline). Because very few of the younger-onset group of the WESDR (10 subjects) or patients with type I diabetes in the ETDRS (10 subjects) reported digoxin use at baseline, all analyses in this report are limited to the older-onset group in the WESDR and patients with type II diabetes in the ETDRS. Analyses are limited to the eyes assigned to deferral of photocoagu-

Table 1—Baseline characteristics of the WESDR and ETDRS patients

	WESDR patients and digoxin use			ETDRS patients and digoxin use		
	Yes	No	P value	Yes	No	P value
n	120	867		117	1,883	
Sex						
M	41	46	0.32	49	53	0.40
F	59	54		51	47	
Insulin use at QV						
Yes	52	49	0.43	85	73	0.005
No	48	51		15	27	
Baseline retinopathy						
None-to-mild NPDR	86	82	0.50	20	21	0.37
Moderate NPDR	3	7		26	32	
Moderately severe NPDR	3	3		36	31	
Severe NPDR	3	2		19	16	
Age (years)	71 ± 9	64 ± 11	<0.001	60 ± 6	56 ± 8	<0.001
Systolic BP (mmHg)	150 ± 25	145 ± 23	0.07	148 ± 24	145 ± 22	0.16
Diastolic BP (mmHg)	75 ± 11	80 ± 12	<0.001	83 ± 11	84 ± 10	0.14
Duration of diabetes (years)	11 ± 8	11 ± 8	0.90	15 ± 7	13 ± 7	0.01
Glycosylated hemoglobin	12 ± 3	11 ± 2	<0.05	9 ± 2	9 ± 2	0.95

Data are % or means ± SD. NPDR, nonproliferative diabetic retinopathy; QV, baseline examination; BP, blood pressure. Glycosylated hemoglobin (%) for WESDR and HbA_{1c} for ETDRS.

lation in the ETDRS. Aspirin use had no effect on the progression of retinopathy in the ETDRS, and analyses are not adjusted for aspirin use.

At the baseline examination in both the WESDR and the ETDRS, data were collected concerning the use of digoxin as well as a number of possible covariables. Analyses for both studies divided patients into those who reported that they were taking digoxin at the baseline examination and those who did not report digoxin use.

Both studies used a modification of the Airlie House retinopathy grading scheme (8). Progression of retinopathy, adjusting for possible known confounders, was defined as the outcome variable for this study. Progression of retinopathy included the development of any retinopathy for people without retinopathy at baseline (WESDR), a two-step change in the modified Airlie House classification scheme (for patients in the WESDR [9] and eyes randomly assigned to deferral of photocoagulation in the ETDRS [8,10]), and the development of proliferative ret-

inopathy in people (WESDR) or eyes (ETDRS) not having it at baseline. Progression was not evaluated for subjects in WESDR or ETDRS who had proliferative retinopathy at the baseline (11).

χ^2 and Student's *t* tests were used to compare the baseline characteristics of the digoxin-treated and non-digoxin-treated groups. To assess the risk of occurrence and progression of retinopathy for patients who used digoxin, while adjusting for other risk factors, a multivariable logistic regression analysis was used for the WESDR data. For the ETDRS data, time to progression could be used as an endpoint, and a Cox proportional hazards model, adjusted for other risk factors, was used to assess the risk of progression of retinopathy for patients who used digoxin.

RESULTS— The baseline characteristics of the WESDR and ETDRS subjects are shown in Table 1. In both studies, those taking digoxin were significantly more likely to be older ($P < 0.001$) than those not taking digoxin. In the WESDR,

those taking digoxin were significantly more likely to have lower diastolic blood pressure and higher glycosylated hemoglobin levels.

Table 2 shows the proportion of patients, both digoxin users and nonusers, who had progression of retinopathy in both studies (based on ~4 years follow-up in the WESDR and at the 4-year annual follow-up visit in the ETDRS); and Table 3 shows the multivariate analysis of digoxin use and retinopathy. There were no statistically significant differences in rates for any of the types of retinopathy progression studied.

As seen in Table 3, regression analyses (logistic regression for the WESDR and Cox regression for the ETDRS) were adjusted for potential confounders (age, duration of diabetes, glycosylated hemoglobin, and baseline retinopathy, as appropriate). The history of digoxin use was not statistically significantly associated with the incidence or progression of diabetic retinopathy in either study for any of the retinopathy progressions studied. The confidence inter-

Table 2—Proportion of patients with progression of retinopathy

	WESDR patients and digoxin use			ETDRS patients and digoxin use		
	Yes	No	P value	Yes	No	P value
n	120	867		117	1,883	
Incident retinopathy	24 of 64 (38)	159 of 411 (39)	0.86	—	—	—
Any two-step progression	31 of 110 (28)	231 of 796 (29)	0.86	56 of 117 (48)	1,069 of 1,883 (57)	0.059
Progression to PDR	6 of 110 (5)	36 of 796 (5)	0.66	50 of 117 (43)	867 of 1,883 (46)	0.49

Data are n (%).

vals (CIs) suggest that as much as a halving or doubling of risk from digoxin use is very unlikely. Because Table 1 shows significantly lower diastolic blood pressures and higher systolic blood pressures in digoxin users in the WESDR, we also examined the effects of systolic and diastolic blood pressures in the multivariate models. Inclusion of these factors had no significant impact on the odds ratios (ORs) (data not shown).

In considering the possibility that some patients might have begun or discontinued digoxin use during the course of the study, we found that 81% of the incidence group and 82% of the progression group in the WESDR who were taking digoxin at baseline were still taking it at follow-up. Baseline digoxin use had no effect on progression of retinopathy in the ETDRS subjects, so we believe the likelihood of an effect during follow-up is very small.

Finally, we examined the possible effect of aspirin in the ETDRS subjects. Aspirin was not associated with progression to proliferative retinopathy ($P =$

0.91) or with a two-step change ($P = 0.74$).

CONCLUSIONS— This study examined the hypothesis that digoxin, a commonly used medication in patients with diabetes, might accelerate diabetic retinopathy because, like diabetes, it also reduces $\text{Na}^+\text{-K}^+\text{-ATPase}$ activity. In terms of understanding the mechanism of diabetic retinopathy, these data neither prove nor disprove that alterations in $\text{Na}^+\text{-K}^+\text{-ATPase}$ activity are involved in the pathogenesis of diabetic retinopathy. However, the data strongly suggest that inhibition of $\text{Na}^+\text{-K}^+\text{-ATPase}$ activity by digoxin in typical clinical situations did not initiate or cause progression of existing retinopathy.

Although digoxin levels were not specifically monitored as part of the WESDR or ETDRS, they are monitored frequently as part of routine clinical practice to maintain therapeutic concentrations of 0.5–2.0 ng/ml (12). It is probable that most patients in these studies who were taking digoxin had appropriate ther-

apeutic levels. Therapeutic digoxin levels typically reduce myocardial $\text{Na}^+\text{-K}^+\text{-ATPase}$ activity by 20–30% (13). However, it is not known to what extent therapeutic plasma digoxin concentrations affect retinal endothelial cells or pericytes, and it is possible that digoxin does not substantially reduce retinal vascular $\text{Na}^+\text{-K}^+\text{-ATPase}$ activity. However, the high-affinity isoforms of the catalytic α subunit of $\text{Na}^+\text{-K}^+\text{-ATPase}$ are probably present in cultured bovine retinal endothelial cells and pericytes (14). Intravitreal injection of ouabain, an inhibitor of $\text{Na}^+\text{-K}^+\text{-ATPase}$ structurally similar to digoxin, inhibits $\text{Na}^+\text{-K}^+\text{-ATPase}$ activity by 20% at 10^{-9} mol/l concentration, equivalent to a serum digoxin concentration of 1 ng/ml (15). Therefore, therapeutic concentrations of digoxin are likely to reduce retinal or retinal vascular $\text{Na}^+\text{-K}^+\text{-ATPase}$ activity. Nevertheless, these data suggest that the combination of diabetes and digoxin does not cause a clinically important additive inhibition of retinal $\text{Na}^+\text{-K}^+\text{-ATPase}$ activity. From a clinical standpoint, these data suggest that digoxin can probably be used in patients with diabetic retinopathy without risk of retinopathy progression or visual deterioration.

Table 3—Multivariable analysis of digoxin and retinopathy

	WESDR		ETDRS	
	OR	95% CI	OR	99% CI
Incidence of retinopathy	0.94	0.49, 1.80	—	—
Two-step progression	0.96	0.56, 1.62	1.20	0.78, 1.82
Progression to PDR	1.18	0.32, 4.32	1.02	0.77, 1.84

Incidence of retinopathy is adjusted for glycosylated hemoglobin and age. Two-step progression and progression to PDR are adjusted for baseline retinopathy, glycosylated hemoglobin, age, and duration of diabetes, as appropriate.

Acknowledgments— This study was supported by National Eye Institute Physician-Scientist Award K11-EY-00331 (to T.W.G.); a grant from Research to Prevent Blindness to the Department of Ophthalmology, Pennsylvania State University College of Medicine; and by National Eye Institute Grant EY-03083 (to R.K.).

References

1. Mazzanti L, Rabini RA, Faloia E, Fumelli P, Bertoli E, DePirro R: Altered cellular Ca^{++} and Na^{+} transport in diabetes mellitus. *Diabetes* 39:850–854, 1990
2. Ohara T, Sussman KE, Draznin B: Effect of diabetes on cytosolic free Ca^{2+} and Na^{+} - K^{+} -ATPase in rat aorta. *Diabetes* 40: 1560–1563, 1991
3. Greene DA, Lattimer SA, Sima AAF: Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. *N Engl J Med* 316: 599–606, 1987
4. Ruderman NB, Williamson JR, Brownlee M: Glucose and diabetic vascular disease. *FASEB J* 6:2905–2914, 1992
5. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. *Arch Ophthalmol* 102:520–526, 1984
6. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. *Arch Ophthalmol* 102:527–532, 1984
7. Early Treatment Diabetic Retinopathy Study Research Group: Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics (ETDRS Report No. 7). *Ophthalmology* 98:741–756, 1991
8. Early Treatment Diabetic Retinopathy Study Research Group: Grading diabetic retinopathy from stereoscopic color fundus photographs: an extension of the modified Airlie House classification (ETDRS Report No. 10). *Ophthalmology* 98: 786–806, 1991
9. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. *Arch Ophthalmol* 107:237–243, 1989
10. Early Treatment Diabetic Retinopathy Study Research Group: Fundus photographic risk factors for progression of diabetic retinopathy (ETDRS Report No. 12). *Ophthalmology* 98:823–833, 1991
11. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. *Arch Ophthalmol* 107:244–249, 1989
12. Hoffman BF, Bigger JT: Digitalis and allied cardiac glycosides. In *The Pharmacologic Basis of Therapeutics*. 8th ed. Goodman AG, Rall TW, Nies AS, Taylor P, Eds. New York, Pergamon, 1990, p. 814–839
13. Akera T, Ng Y-C: Digitalis sensitivity of Na^{+} , K^{+} -ATPase, myocytes and the heart. *Life Sci* 48:97–106, 1991
14. Gardner TW, Bonsall DJ, Kule C, Ng Y-C, Brennan WA Jr: Sodium-potassium ATPase isoform expression in bovine retinal vascular cells (Abstract). *Invest Ophthalmol Vis Sci* 33 (Suppl.):1362, 1992
15. Langham ME, Ryan SJ, Kostelnik M: The Na,K ion dependent adenosine triphosphatase of the retina and the mechanism of visual loss caused by cardiac glycosides. *Life Sci* 6:2037–2047, 1967